Marché mondial de la cardiomyopathie – Tendances et prévisions de l'industrie jusqu'en 2028

Analyse et perspectives du marché : Marché mondial de la cardiomyopathie

Le marché de la cardiomyopathie devrait connaître une croissance exponentielle au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché connaît une croissance de 7,90 % au cours de la période de prévision de recherche mentionnée ci-dessus. L'augmentation de la population gériatrique et la prévalence croissante de l'insuffisance cardiaque pourraient stimuler la croissance du marché.

En outre, les marchés émergents et les investissements massifs dans la recherche et le développement stimulent également la croissance du marché. En outre, l'augmentation des dépenses de santé et la présence de thérapies en cours de développement constituent des opportunités de croissance du marché. Cependant, les effets indésirables liés aux médicaments, le manque de traitement efficace associé à la méconnaissance de la maladie et à un cadre réglementaire strict, entre autres, peuvent entraver le marché mondial de la cardiomyopathie.

La cardiomyopathie est une maladie associée au muscle cardiaque. Elle affecte les personnes de tout âge et entraîne des conséquences à vie. Elle peut entraîner une insuffisance cardiaque. Il existe plusieurs types de cardiomyopathie, notamment la cardiomyopathie hypertrophique, dilatée et restrictive. Les symptômes courants associés à la cardiomyopathie comprennent l'essoufflement, le ballonnement de l'abdomen, le gonflement des jambes, des chevilles et des pieds, la toux, la fatigue, l'inconfort thoracique, les étourdissements, entre autres. Les patients qui souffrent déjà d'hypertension artérielle à long terme, d'un rythme cardiaque rapide chronique, de troubles métaboliques (maladies thyroïdiennes ou diabète) et de sarcoïdose, entre autres, présentent un risque élevé de développer une cardiomyopathie. La cardiomyopathie peut être diagnostiquée à l'aide d'une radiographie pulmonaire, d'un échocardiogramme et d'un cathétérisme cardiaque, d'une IRM cardiaque, d'un scanner, d'une analyse sanguine, d'un test génétique et d'un test de carénage, entre autres. Il existe plusieurs options de traitement indiquées pour le traitement de la myopathie cardiaque, notamment des médicaments, des dispositifs implantables, des pompes cardiaques, des défibrillateurs cardioverteurs, entre autres.

The prevalence of heart failure is increasing worldwide with reported 64.34 worldwide cases. This affected population is largely dependent upon the effective treatment options in order to lead a disease free life and hence expected to provide market with the lucrative growth. It is also estimated that cardiomyopathy market is growing with the CAGR of 7.90% in 2020.

This cardiomyopathy market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Cardiomyopathy Market Scope and Market Size

Cardiomyopathy market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the cardiomyopathy market is segmented into hypertrophic, dilated and restrictive cardiomyopathy.
• On the basis of diagnosis, the cardiomyopathy market is segmented into X- ray, echocardiogram, electrocardiogram, MRI, CT scan, blood tests among others.
• On the basis of treatment, the cardiomyopathy market is segmented into medication, implantable devices, heart pumps, cardioverter-defibrillators among others. Medication segment is further sub-segmented into ACE inhibitors, ARBs, beta-blockers among others. ACE inhibitors is further sub-segmented into benazepril, captopril, enalapril, fosinopril, Lisinopril, moexipril, perindopril, quinapril among others. ARBs is further sub-segmented into azilsartan, candesartan, losartan, valsartan, telmisartan, olmesartan among others. Beta- blockers sub-segmented into acebutolol, atenolol, metoprolol, nebivolol, nadolol, propranolol among others.
• On the basis of route of administration, the cardiomyopathy market is segmented into oral, parenteral and others.
• On the basis of end-users, the cardiomyopathy market is segmented into clinics, hospitals and others.
• On the basis of distribution channel, the cardiomyopathy market has also been segmented into direct tenders, retail sales, hospital pharmacy, retail pharmacy, online pharmacy and others. 

Cardiomyopathy Market Country Level Analysis

Cardiomyopathy market is analysed and market size information is provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the cardiomyopathy market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to the rising incidence of heart diseases and presence of refined healthcare facilities. Europe is also expected to grow exponentially due to technological advancements and rising initiatives by market players to expand the product distribution network. Asia-Pacific is expected to account for the largest market share due to the developing healthcare facilities and presence of large number of generic drug manufacturers.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Cardiomyopathy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Cardiomyopathy Market Share Analysis

Cardiomyopathy market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to cardiomyopathy market.

Les principaux acteurs couverts sur le marché de la cardiomyopathie sont Novartis AG, GlaxoSmithKline plc, Cipla Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Zensun, Hikma Pharmaceuticals PLC, Endo International Inc, Zydus Cadila, Capricor Therapeutics, MyoKardia, Aastrom Biosciences, t2cure GmbH, Boston Scientific Corporation, Covance, Mylan NV, Pfizer, Inc., BG Medicine Inc., Biomerieux et Bio-Rad Laboratories, entre autres acteurs nationaux et mondiaux. Les analystes de DBMR comprennent les atouts concurrentiels et fournissent une analyse concurrentielle pour chaque concurrent séparément.

SKU-54395